REFERENCES
1. Marsico G, Martin-Saldaña S, Pandit A. Therapeutic biomaterial approaches to alleviate chronic limb threatening ischemia. Adv Sci 2021;8:2003119.
2. Veith AP, Henderson K, Spencer A, Sligar AD, Baker AB. Therapeutic strategies for enhancing angiogenesis in wound healing. Adv Drug Deliv Rev. 2019;146:97-125.
3. Järvinen TAH, Pemmari T. Systemically administered, target-specific, multi-functional therapeutic recombinant proteins in regenerative medicine. Nanomaterials. 2020;10:226.
4. Chu H, Wang Y. Therapeutic angiogenesis: controlled delivery of angiogenic factors. Ther Deliv. 2012;3:693-714.
5. Elsharkasy OM, Nordin JZ, Hagey DW, et al. Extracellular vesicles as drug delivery systems: why and how? Adv Drug Deliv Rev 2020;159:332-43.
6. Murphy DE, de Jong OG, Brouwer M, et al. Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking. Exp Mol Med. 2019;51:1-12.
7. Kwon S, Shin S, Do M, et al. Engineering approaches for effective therapeutic applications based on extracellular vesicles. J Control Release. 2021;330:15-30.
8. Varderidou-Minasian S, Lorenowicz MJ. Mesenchymal stromal/stem cell-derived extracellular vesicles in tissue repair: challenges and opportunities. Theranostics. 2020;10:5979-97.
9. Nallakumarasamy A, Jeyaraman M, Maffulli N, et al. Mesenchymal stromal cell-derived extracellular vesicles in wound healing. Life. 2022;12:1733.
10. Bhat A, Malik A, Yadav P, Ware WJ, Kakalij P, Chand S. Mesenchymal stem cell‐derived extracellular vesicles: recent therapeutics and targeted drug delivery advances. J of Extracellular Bio. 2024;3:e156.
11. Saba E, Sandhu MA, Pelagalli A. Canine mesenchymal stromal cell exosomes: state-of-the-art characterization, functional analysis and applications in various diseases. Vet Sci. 2024;11:187.
12. Sun Y, Sun F, Xu W, Qian H. Engineered extracellular vesicles as a targeted delivery platform for precision therapy. Tissue Eng Regen Med. 2023;20:157-75.
13. Obuchi W, Zargani-Piccardi A, Leandro K, et al. Engineering of CD63 enables selective extracellular vesicle cargo loading and enhanced payload delivery. J Extracell Vesicles. 2025;14:e70094.
14. Liang X, Gupta D, Xie J, et al. Engineering of extracellular vesicles for efficient intracellular delivery of multimodal therapeutics including genome editors. Nat Commun 2025;16:4028.
15. Stickney Z, Losacco J, McDevitt S, Zhang Z, Lu B. Development of exosome surface display technology in living human cells. Biochem Biophys Res Commun. 2016;472:53-9.
16. Kooijmans SAA, Schiffelers RM, Zarovni N, Vago R. Modulation of tissue tropism and biological activity of exosomes and other extracellular vesicles: new nanotools for cancer treatment. Pharmacol Res. 2016;111:487-500.
17. Corso G, Heusermann W, Trojer D, et al. Systematic characterization of extracellular vesicle sorting domains and quantification at the single molecule - single vesicle level by fluorescence correlation spectroscopy and single particle imaging. J Extracell Vesicles. 2019;8:1663043.
18. Curley N, Levy D, Do MA, et al. Sequential deletion of CD63 identifies topologically distinct scaffolds for surface engineering of exosomes in living human cells. Nanoscale. 2020;12:12014-26.
19. Ivanusic D, Denner J. The large extracellular loop is important for recruiting CD63 to exosomes. MicroPubl Biol. 2023;2023.
20. Roefs MT, Gamauf J, Kroenigsberger B, et al. Rapid extracellular vesicle surface decoration with targeting moieties based on a fluorescein binding single chain variable fragment snorkel. J Control Release. 2026;390:114558.
21. Zhang J, Brown A, Johnson B, et al. Genetically engineered extracellular vesicles harboring transmembrane scaffolds exhibit differences in their size, expression levels of specific surface markers and cell-uptake. Pharmaceutics. 2022;14:2564.
22. Zhang C, Wu Y, Wang Y, et al. Bioengineering of extracellular vesicles with scaffold proteins for drug delivery. J Nanobiotechnology. 2026;24:160.
23. Scattini G, Pianigiani G, Capomaccio S, et al. Hacking extracellular vesicles: using vesicle-related tags to engineer mesenchymal stromal cell-derived extracellular vesicles. Pharmaceutics. 2025;17:1435.
24. Caccuri F, Giagulli C, Bugatti A, et al. HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc Natl Acad Sci U S A. 2012;109:14580-5.
25. Alcami A. Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol. 2003;3:36-50.
26. Caccuri F, D'Ursi P, Uggeri M, et al. Evolution toward beta common chain receptor usage links the matrix proteins of HIV-1 and its ancestors to human erythropoietin. Proc Natl Acad Sci U S A. 2021;118:e2021366118.
27. Ratner L, Starcich B, Josephs SF, et al. Polymorphism of the 3’ open reading frame of the virus associated with the acquired immune deficiency syndrome, human T-lymphotropic virus type III. Nucleic Acids Res. 1985;13:8219-29.
28. Giagulli C, Marsico S, Magiera AK, et al. Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells. PLoS One. 2011;6:e17831.
29. Scattini G, Pellegrini M, Severi G, Cagiola M, Pascucci L. The stromal vascular fraction from canine adipose tissue contains mesenchymal stromal cell subpopulations that show time-dependent adhesion to cell culture plastic vessels. Animals. 2023;13:1175.
30. Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13:e12404.
31. Clark-Lewis I, Dewald B, Loetscher M, Moser B, Baggiolini M. Structural requirements for interleukin-8 function identified by design of analogs and CXC chemokine hybrids. J Biol Chem. 1994;269:16075-81.
32. Bugatti A, Giagulli C, Urbinati C, et al. Molecular interaction studies of HIV-1 matrix protein p17 and heparin: identification of the heparin-binding motif of p17 as a target for the development of multitarget antagonists. J Biol Chem. 2013;288:1150-61.
33. Han J, Luo L, Marcelina O, Kasim V, Wu S. Therapeutic angiogenesis-based strategy for peripheral artery disease. Theranostics. 2022;12:5015-33.
34. Klyachko NL, Arzt CJ, Li SM, Gololobova OA, Batrakova EV. Extracellular vesicle-based therapeutics: preclinical and clinical investigations. Pharmaceutics. 2020;12:1171.
35. Yeo RW, Lai RC, Zhang B, et al. Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv Drug Deliv Rev. 2013;65:336-41.
36. Vazdar M, Heyda J, Mason PE, et al. Arginine “magic”: guanidinium like-charge ion pairing from aqueous salts to cell penetrating peptides. Acc Chem Res. 2018;51:1455-64.
38. Bruno S, Grange C, Deregibus MC, et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol. 2009;20:1053-67.
39. Zhu Y, Liao ZF, Mo MH, Xiong XD. Mesenchymal stromal cell-derived extracellular vesicles for vasculopathies and angiogenesis: therapeutic applications and optimization. Biomolecules. 2023;13:1109.
40. Zhang X, Che X, Zhang S, et al. Mesenchymal stem cell-derived extracellular vesicles for human diseases. Extracell Vesicles Circ Nucl Acids. 2024;5:64-82.
41. Esmaeili A, Baghaban Eslaminejad M, Hosseini S. Biomolecular corona potential in extracellular vesicle engineering for therapeutic applications. Biomed Pharmacother. 2025;188:118202.
42. Xu H, Liu R, Zhou H, et al. Engineered small extracellular vesicles as bioactive materials: Integrating engineering strategies for cargo loading and targeted delivery systems. Bioact Mater. 2026;59:96-134.
43. Chiodi E, Daaboul GG, Marn AM, Ünlü MS. Multiplexed affinity measurements of extracellular vesicles binding kinetics. Sensors. 2021;21:2634.
44. Omidian H, Cubeddu LX, Wilson RL. Peptide-functionalized nanomedicine: advancements in drug delivery, diagnostics, and biomedical applications. Molecules. 2025;30:1572.
